Today

Agents

Chat

Arena

Discover

More

App

Lilly targets Q1 2027 FDA filing for retatrutide obesity approval - LLY News | Rallies

Lilly targets Q1 2027 FDA filing for retatrutide obesity approval

LLY•2026-07-23

Lilly plans FDA filing for retatrutide in Q1 2027

Eli Lilly plans to file a Biologics License Application with the FDA for obesity drug candidate retatrutide in Q1 2027.

Related News

Suburban Propane Partners declares quarterly distribution of $0.325 per unit

SPH•2026-07-23

Pool Corp Q2 FY26 diluted EPS flat at 5.17; net sales rise 2% to 1.8 billion

POOL•2026-07-23

Incannex starts screening patients in Phase 2 DReAMzz trial of IHL-42X for sleep apnea

IXHL•2026-07-23

C

Civista Bancshares Q2 profit rises 30%, interest margin expands

CIVB•2026-07-23

Luxembourg's Altisource Q2 service revenue rises on customer wins

ASPS•2026-07-23